



Four databases (Medline, Embase, Web of Science and the Cochrane Library) were searched up to 
November 2020 using the following terms: (Transcatheter aortic valve implantation (TAVI) OR 
Transcatheter Aortic Valve Replacement (TAVR) OR Percutaneous aortic valve replacement/ implantation) 
AND (femoral artery OR transfemoral) AND (Ultrasonography OR echography OR fluoroscopy OR 
angiography). The detailed search strategy used is also shown on PROSPERO (CRD42020218259). The 
resultant titles and abstracts of the search were screened by three reviewers (JJHB, SR and RAK) for 
relevance. Then full texts were assessed for eligibility (Figure 1). 
Detailed search strategy 
Medline 
1 exp transcatheter aortic valve implantation/ 6107 
2 Transcatheter aortic valve implantation.ti,ab. 5211 
3 TAVI.ti,ab. 4225 
4 exp Transcatheter Aortic Valve Replacement/ 6107 
5 Transcatheter aortic valve replacement.ti,ab. 4439 
6 TAVR.ti,ab. 3363 
7 Percutaneous aortic valve replacement.ti,ab. 189 
8 percutaneous aortic valve implantation.ti,ab. 118 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 11826 
10 exp Femoral Artery/ 28820 
11 femoral artery.ti,ab. 17734 
12 transfemoral.ti,ab. 5460 
13 10 or 11 or 12 42287 
14 exp Ultrasonography/ or (ultrasound or ultrason* or 
echograph*).ti,ab. 
635204 
15 exp fluoroscopy/ or fluoroscop*.ti,ab. 39546 
16 exp angiography/ or angiog*.ti,ab. 452324 
17 14 or 15 or 16 1070170 




1 exp transcatheter aortic valve implantation/ 22618 
2 Transcatheter aortic valve implantation.ti,ab. 9897 
3 TAVI.ti,ab. 10090 
4 exp Transcatheter Aortic Valve Replacement/ 22618 
5 Transcatheter aortic valve replacement.ti,ab. 7953 
6 TAVR.ti,ab. 7210 
7 Percutaneous aortic valve replacement.ti,ab. 329 
8 percutaneous aortic valve implantation.ti,ab. 218 
9 1 or 2 or 3 or 4 or 5 or 6 or 7 or 8 25520 
10 exp Femoral Artery/ 34463 
11 femoral artery.ti,ab. 25720 
12 transfemoral.ti,ab. 9367 
13 10 or 11 or 12 50752 
14 exp Ultrasonography/ or (ultrasound or ultrason* or 
echograph*).ti,ab. 
1091052 
15 exp fluoroscopy/ or fluoroscop*.ti,ab. 66362 
16 exp angiography/ or angiog*.ti,ab. 638256 
17 14 or 15 or 16 1673462 
18 9 and 13 and 17 1720 
 
Cochrane Library 
ID Search Hits 
#1 MeSH descriptor: [Transcatheter Aortic Valve Replacement] explode all trees 150 
#2 "Transcatheter aortic valve implantation" 635 
#3 TAVI 381 
#4 ("Transcatheter aortic valve replacement"):ti,ab,kw 490 
#5 TAVR 433 
#6 "Percutaneous aortic valve replacement" 1 
#7 "percutaneous aortic valve implantation" 7 
#8 (2-#7) 918 
#9 MeSH descriptor: [Femoral Artery] explode all trees 991 
#10 "femoral artery" 2214 
#11 transfemoral 612 
#12 (3-#11) 2680 
#13 MeSH descriptor: [Ultrasonography] explode all trees 13623 
#14 (ultrasound or ultrason* or echograph*) 44573 
#15 MeSH descriptor: [Fluoroscopy] explode all trees 627 
#16 fluoroscop* 3483 
#17 MeSH descriptor: [Angiography] explode all trees 7178 
#18 angiog* 23923 
#19 {OR #13-#18} 73402 
#20 (4, #12, #19) 50 
 
Web of Science 
# 9 193 #8 AND #5 AND #4  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 8 693,190 #7 OR #6  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 7 298,600 ((TS=(fluoroscop* OR 
angiog*) ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 6 415,203 ((TS=(ultrasound OR ultrason* OR 
echograph*) ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 5 17,479 ((TS=("Femoral Artery" OR 
"transfemoral") ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 4 6,771 #3 OR #2 OR #1  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 3 212 ((TS=("Percutaneous aortic valve replacement" OR 
"percutaneous aortic valve 
implantation") ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 2 3,155 ((TS=("Transcatheter Aortic Valve Replacement" OR 
"TAVR") ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
# 1 4,326 ((TS=("Transcatheter aortic valve implantation" OR 
"TAVI") ))  AND DOCUMENT  TYPES: (Article)  
Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-
SSH, ESCI Timespan=All years 
   
Data extraction 
Study design and patient characteristics were derived and input in abbreviated summary into tables. Where 
not explicitly stated, range of sheath sizes were estimated from reported valve type and size. Outcomes 
were transferred in the form of crude dichotomous events. Studies that controlled for multiple confounders 
were extracted in the form of adjusted odds ratios (ORs) and standard errors calculated from 95% 
confidence intervals (95% CIs) or as event rates in propensity-matched studies. Where data on total 
complication rates was not provided, it was calculated by combining major and minor rates. 
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Kotronias 202017 Total 
83 
(79-86) 
































































Moriyama 201918 Total - - - - - - - 













Fluoroscopy STS: 7.9 
Antiplatelet therapy refers to single or dual antiplatelet therapy. Euro: Logistic EuroSCORE II; STS: The 
Society of Thoracic Surgeons Score; PAD: peripheral arterial disease.  
Table II. Risk of bias assessment of outcomes according to ROBINS-I (Risk Of Bias In Non-randomised Studies of Interventions)  
First author, Year 
(Ref. #) 












Bias due to 
missing data 







Overall risk of 
bias judgment  
Major and minor access site vascular complications 
Kotronias, 202017 Moderate Low Low Low Low Moderate Low Moderate 
Potluri, 202019 Serious Low Low Low No information Low Low Serious 
Vincent, 20207 Moderate Low Low Low Low Moderate Low Moderate 
Witberg, 202021 Moderate Low Low Low No information Moderate Low Moderate 
Bouteau, 201914,15 Serious Low Low Low Low Low Low Serious 
Moriyama, 201918 Moderate Low Low Low No information No information No information Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Major access site vascular complications 
Kotronias, 202017 Moderate Low Low Low Low Moderate Low Moderate 
Potluri, 202019 Serious Low Low Low No information Low Low Serious 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Bouteau, 201914,15 Serious Low Low Low Low Low   Low Serious 
Moriyama, 201918 Moderate  Low Low Low No information No information No information Moderate 
Khan, 201916 Serious No information Low Low No information No information No information Serious 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Minor access site vascular complications 
Kotronias, 202017 Moderate Low Low Low Low Moderate Low Moderate 
Potluri, 202019 Serious Low Low Low No information Low Low Serious 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Bouteau, 201914,15 Serious Low Low Low Low Low   Low Serious 
Moriyama, 201918 Moderate  Low Low Low No information No information No information Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Life-threatening, major and minor access site bleeding complications 
Kotronias, 202017 Serious Low Low Low Low Moderate Low Serious 
Potluri, 2020*,20 Serious No information Low Low No information No information No information Serious 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Life-threatening and major access site bleeding complications 
Kotronias, 202017 Serious Low Low Low Low Moderate Low Serious 
Potluri, 2020*,20 Serious No information Low Low No information No information No information Serious 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Moriyama, 201918 Moderate  Low Low Low No information No information No information Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Minor access site bleeding complications 
Kotronias, 202017 Serious Low Low Low Low Moderate Low Serious 
Potluri, 2020*,20 Serious No information Low Low No information No information No information Serious 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
Transfusion of red blood cells 
Vincent, 20207 Moderate Low  Low  Low  Low  Moderate Low Moderate 
Witberg, 202021 Moderate  Low Low Low No information Moderate Low Moderate 
Elbaz-Greener, 20176 Serious Low Low Low Low Moderate Low Serious 
*Since the study by Potluri and colleagues19 did not report sufficient data to ascertain access site-related bleeding complications, bleeding outcomes were taken from Basra and 
colleagues20; a study from the same center and authors with an overlapping study time periods that provided sufficient data to adjudicate bleeding events as access site-related. 
Quality assessment was based on the information that was available in Basra and colleagues.  
Table III. GRADE Assessment of overall strength of evidence 















Major and minor access site vascular complications 
















62 fewer per 
1,000 
(from 88 





Major access site vascular complications 








demonstrated effect  





32 fewer per 
1,000 
(from 44 





Minor access site vascular complications 
















31 fewer per 
1,000 
(from 47 





Life threatening, major and minor access site bleeding complications 































46 fewer per 
1,000 
(from 70 
fewer to 11 
more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Life-threatening and major access site bleeding complications 








demonstrated effect  
75/1539 (4.9%)  87/1221 (7.1%)  OR 0.52 
(0.26 to 
1.04)  
33 fewer per 
1,000 
(from 52 
fewer to 3 
more)  
⨁◯◯◯ 
VERY LOW  
CRITICAL  
Minor access site bleeding complications 








demonstrated effect  
70/1404 (5.0%)  56/1086 (5.2%)  OR 0.67 
(0.34 to 
1.31)  
16 fewer per 
1,000 
(from 33 
fewer to 15 
more)  
⨁◯◯◯ 




Transfusion of red blood cells 























demonstrated effect  
78/902 (8.6%)  68/846 (8.0%)  OR 0.73 
(0.19 to 
2.74)  
20 fewer per 
1,000 
(from 64 
fewer to 113 
more)  
⨁◯◯◯ 
VERY LOW  
IMPORTANT  
a very serious risk of bias is due to the inclusion of studies of moderate to high risk of bias according to the Robins I tool. b: serious, moderate variation in point estimates with some overlap in CIs and substantial 
heterogeneity. c: unimportant as studies represent a selection of valve systems with varying prevalence of peripheral arterial disease. d: not serious as confidence intervals do not overlap with line of no effect with 
adequate total number of events. e: Unimportant, some variation in point estimates with large overlap in CIs and moderate heterogeneity.  f: serious as confidence intervals overlap with line of no effect with generally 
small number of events. g:serious as confidence intervals overlap with line of no effect despite the adequate number of events. CI: Confidence interval; OR: Odds ratio. 
Table IV. Outcomes according to imaging modality 











Major and minor access site VCs 22/393 (5.6%) 21/125 (16.8%) 0.33 (0.11-0.94) 
Major access site VCs 12/393 (3.05%) 7/125 (5.6%) 0.53 (0.20-1.38) 
Minor access site VCs 10/393 (2.54%) 14/125 (11.2%) 0.31 (0.11-0.85) 
Life-threatening, major and minor access site BCs 17/393 (4.33%) 12/125 (9.6%) - 
Life-threatening and major access site BCs 10/393 (2.54%) 3/125 (2.4%) - 




Major and minor access site VCs 27/380 (7.9%) 29/232 (14.2%) - 
Major access site VCs 12/380 (3.2%) 13/232 (5.6%) - 
Minor access site VCs 15/380 (3.9%) 16/232 (6.9%) - 
Life-threatening, major and minor access site BCs*
†
 5/109 (4.59%) 9/115 (7.83%) - 
Major and life-threatening access site BCs
†
 5/109 (4.59%) 7/115 (6.09%) - 
Minor access site BCs
†




Major and minor access site VCs 13/95 (13.7%) 28/95 (29.5%) 0.37 (0.17-0.77) 
Major access site VCs 4/95 (4.2%) 12/95 (12.6%) 0.31 (0.12-0.85) 
Minor access site VCs 9/95 (9.5%) 16/95 (16.8%) 0.61 (0.24-1.52) 
Life-threatening, major and minor access site BCs 13/95 (13.7%) 26/95 (27.4%) 0.42 (0.20-0.88) 
Life-threatening and major access site BCs 4/95 (4.2%) 12/95 (12.6%) 0.30 (0.09-0.96) 
Minor access site BCs 9/95 (9.5%) 14/95 (14.7%) 0.61 (0.25-1.48) 




Major and minor access site VCs 36/529 (6.8%) 43/642 (6.7%) 1.12 (0.65-1.96) 
Major access site VCs 16/529 (3.0%) 16/642 (2.6%) 1.14 (0.51-2.78) 
Minor access site VCs 20/529 (3.8%) 27/642 (4.0%) 0.89 (0.39-2.04) 
Life-threatening, major and minor access site BCs 34/529 (6.4%) 38/642 (5.9%) 1.06 (0.61-1.92) 
Life-threatening and major access site BCs* 19/529 (3.6%) 18/642 (2.8%) - 
Life-threatening access site BCs 8/529 (1.5%) 11/642 (1.7%) 0.83 (0.59-3.13) 
Major access site BCs 11/529 (2.1%) 7/642 (1.1%) 1.35 (0.40-3.23) 
Minor access site BCs 15/529 (2.8%) 20/642 (3.1%) 0.80 (0.58-3.45) 





Major and minor access site VCs* 61/340 (17.9%) 51/222 (23.0%) - 
Major access site VCs 19/340 (5.6%) 23/222 (10.4%) - 




Major and minor access site VCs* 5/135 (3.7%) 21/135 (15.6 0.21 (0.08-0.57) 
Major access site VCs  2/135 (1.5%) 10/135 (7.4%) 0.19 (0.04-0.87) 
Minor access site VCs  3/135 (2.2%) 11/135 (8.2%) 0.26 (0.07-0.94) 










Major and minor access site VCs* 56/278 (20.2%) 38/109 (34.9%) - 
Major access site VCs 33/278 (11.9%)  28/109 (25.7%)  - 
Minor access site VCs 23/278 (8.3%) 10/109 (9.2%)  - 
Life-threatening, major and minor access site BCs* 74/278 (26.6%) 46/109 (42.2%) - 
Major and life-threatening access site BCs 35/278 (12.6%) 35/109 (32.1%)  - 
Major access site BCs 30/278 (10.8%)  28/109 (25.7%)  - 
Minor access site BCs 39/278 (14.0%)  11/109 (10.1%)  - 
Transfusion of RBCs 23/278 (8.3%)  24/109 (22.0%)  - 
*: calculated from already known data assuming life-threatening, major and minor categories are assumed 
as separate entities, as per VARC criteria. †: Since the study by Potluri and colleagues19 did not report sufficient 
data to ascertain access site related bleeding complications, bleeding outcomes were taken from Basra and 
colleagues20; a study from the same center and authors with a overlapping study time periods that provided 
sufficient data to adjudicate bleeding events as access site related; BCs: Bleeding complications; RBCs: red 
blood cells; VARC-2: Valve Academic Research Consortium-2; VCs: vascular complications. 
  











Total access site vascular complications 0.44 (0.20-0.99) 
Major access site vascular complications 0.49 (0.24-1.02) 
Minor access site vascular complications 0.51 (0.29-0.90) 
Total access site bleeding complications 0.69 (0.28-1.70) 
Life-threatening and major access site 
bleeding complications 
0.23 (0.09-0.60) 
Minor access site bleeding complications 0.70 (0.37-1.31) 
Transfusion of red blood cells 0.66 (0.13-3.27) 
‘Moderate’ 
Risk of Bias 
only 
Total access site vascular complications 0.42 (0.20-0.89) 
Major access site vascular complications 0.51 (0.23-1.16) 
Minor access site vascular complications 0.43 (0.20-0.90) 
Total access site bleeding complications 0.71 (0.28-1.80) 
Life-threatening and major access site 
bleeding complications 
0.44 (0.12-1.71) 
Minor access site bleeding complications 0.78 (0.46-1.34) 
Transfusion of red blood cells 1.47 (0.97-2.22) 
Analysis 
methods 
Inverse variance No change 
Fixed effect 
meta-analysis 
Total access site vascular complications 0.56 (0.46-0.69) 
Major access site vascular complications 0.51 (0.38-0.68) 
Minor access site vascular complications 0.66 (0.51-0.86) 
Total access site bleeding complications 0.63 (0.48-0.82) 
Life-threatening and major access site 
bleeding complications 
0.52 (0.37-0.72) 
Minor access site bleeding complications 0.79 (0.54-1.15) 





Total access site vascular complications 0.45 (0.32-0.63) I2: 47% 
Minor access site vascular complications 0.75 (0.55-1.02) I2: 12% 
reach I2 <50% Total access site bleeding complications 0.47 (0.34-0.66) I2: 0% 
Life-threatening and major access site 
bleeding complications 
0.39 (0.22-0.68) I2: 30% 
Minor access site bleeding complications 0.94 (0.59-1.49) I2: 10% 
Moderate Risk of Bias shows outcomes following the removal of studies at ‘Serious’ Risk of Bias. ‘Total’: major 
and minor vascular complications/ life-threatening, major and minor bleeding complications. CI: confidence 
interval; I2: heterogeneity; OR: odds ratio
Table VI. Table indicating methods of adjustment and covariates of adjustment. 
Study Outcome Method Adjustment covariates 
Kotronias 202018 Vascular complications Multivariate logistic regression 
Year of operation, LV-guidewire pacing, peripheral 
arterial disease 
Vincent 20207 
Vascular and bleeding 
complications 
Propensity matching 
Age, gender, BMI, NYHA class III or IV, STS-PROM 
Score, Anticoagulant, Diabetes, Hypertension, Coronary 
artery disease, prior cerebrovascular disease, chronic 
obstructive airways disease, peripheral arterial disease; 
prior atrial fibrillation,, renal function, LVEF, aortic 
valve area, mean aortic gradient, primary access sheath 
size, secondary access sheath size, prosthesis size, 
sheath to femoral artery ratio 
Witberg 202021 
Vascular and bleeding 
complications 
Multivariate logistic regression 
Age, sex, diabetes mellitus, glomerular filtration rate, 
previous stroke or transient ischaemic attack, peripheral 
vascular disease, body mass index, frailty, and general 
anaesthesia 
Moriyama 201918 Vascular complications Propensity matching No information available 
BMI: Body mass index; LV: left ventricle; LVEF: left ventricle ejection fraction; NYHA: New York Heart Association; STS-PROM: Society of Thoracic Surgeons 30-Day 






Figure I  
 
Figure I: Meta-analyses evaluating maximally adjusted risk of life-threatening, 
major and minor access site bleeding complications (S1A), life-threatening and 
major access site bleeding complications (S1B) and minor access site bleeding 
complications (S1C) of an ultrasound-guided versus fluoroscopy-guided TAVR 
access strategy. 
